



Technical Report No. 85

Enhanced Test Methods for Visible Particle Detection and Enumeration on Elastomeric Closures and Glass Containers

Enhanced Test Methods for Visible Particle Detection and Enumeration on Elastomeric Closures and Glass Containers Team

Authors

Core Team

Tia Bush , Amgen (Chair)	Anthony Perry , Schott
John Ayres , MD, Pharma Safety Solutions	John Shabushnig , Ph.D., Insight Pharma Consulting
Cecile Begat , Bayer	Xu Song , MEng, Astra Zeneca
Antonio Burazer , Takeda	Hervé Soukiassian , MEng, BD
Fran DeGrazio , West Pharmaceutical Services	Andrew Spasoff , MS, Astra Zeneca
Carol Flynn , MEng, Corning	Amy Stanton , Amgen
Abizer Harianawala , Stevanato Group	Dorothee Streich , Ph.D., Bayer
Paul Kinsey , GSK	Rick Watson , Merck
Jahanvi Miller , MBA, PDA	

Elastomer Subteam

Ravi Patel , West Pharmaceutical Services (Co-Chair)	Gert Gregoire , MBA, Datwyler
John Rech , West Pharmaceutical Services (Co-Chair)	Lucia Ino , West Pharmaceutical Services
Andrea DeSalvia , Aptar	Denise Schnaufer , Merck
Wadi Farach , MEng, Amgen	Larry Staub , MS, Quality Advisor
	Julie Suman , Next Breath
	Rick Watson , Merck

Glass Subteam

Hervé Soukiassian , MEng, BD (Co-Chair)	Martina Marchioro , Stevanato Group
Paul Kinsey , GSK (Co-Chair)	Didier Morel , BD
Alfred Breunig , Nipro Pharma Packaging	Anthony Perry , Schott
Benjamin Coutan , MBA, Gerresheimer	Volker Rupertus , Schott AG
Wadi Farach , MEng, Amgen	Daniele Zuccato , Schott AG
Carol Flynn , MEng, Corning Incorporated	

Contributors

Jean Bernard Theo , BMS	Abriana Rozentsvayg , MS, Pfizer
Buffy Hudson-Curtis , PhD, GSK	Christian Schwarz , Amgen
Swen Maas , Material Analytischer Service	Linda Wildling , PhD, Takeda

Acknowledgements

The authors wish to thank the Pharmaceutical Manufacturers Forum (PMF) for their encouragement and support in development of these studies. We wish to further thank the following companies for their participation in the studies documented herein: Amgen Inc., Aptar, Bayer AG, BD, Bristol Myers Squibb, Corning Inc, Datwyler, Gerresheimer AG, GlaxoSmithKline, Material Analytischer Service, Nipro Pharma Packaging, Stevanato Group, Schott, Takeda, and West Pharmaceutical Services.

Enhanced Test Methods for Visible Particle Detection and Enumeration on Elastomeric Closures and Glass Containers

Technical Report No. 85

ISBN: 978-1-945584-26-8

© 2021 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	5.0 GLASS CONTAINER INSPECTION METHOD.....	11
1.1 Purpose	1	5.1 Inspection of Ready-to-Use Empty Glass Containers	11
1.2 Scope	1	5.1.1 Operator Training for the Enhanced Container Inspection Method.....	12
2.0 GLOSSARY AND ABBREVIATIONS.....	2	5.1.2 Equipment and Setup	12
2.1 Abbreviations.....	3	5.1.3 Magnification Requirements To Inspect Glass Containers.....	14
3.0 CURRENT STATE OF VISUAL INSPECTION FOR PARTICLES.....	3	5.1.4 Glass Container Inspection Procedure	14
3.1 Patient Risk Assessment.....	4	5.2 Method Qualification Strategy and Detection	15
3.2 Existing Test Methods and Limitations	5	5.3 Study Design	17
3.2.1 ISO Test Method 8871-3	6	5.3.1 Normalizing the Particle Size	18
3.2.2 U.S. Pharmacopeia Methods	6	6.0 CONCLUSION	19
3.2.3 European Pharmacopeia Methods	7	7.0 REFERENCES.....	20
3.2.4 Japanese Pharmacopeia Methods.....	7	8.0 APPENDICES.....	21
3.3 Conclusion.....	7	8.1 Appendix A. Additional Information on Enhanced Closures Testing Method Development.....	21
4.0 ELASTOMERIC CLOSURES TEST METHOD	8	8.2 Appendix B. Method: Determination of Visible Particles and Fibers on Elastomeric Components by Membrane Filtration and Microscopic Examination	34
4.1 Enhanced Closures Testing Method Development	8	8.3 Appendix C. Additional Information on Empty Glass Inspection Capability Studies	36
4.1.1 Size Threshold	8	8.4 Appendix D. Method: Visual Inspection of Empty Glass Containers	44
4.1.2 Novel Particle Size Measurement Tool	10		
4.2 Summary for Performing the Enhanced Closures Testing Method	10		
4.3 Method Qualification Strategy and Lessons Learned.....	11		

FIGURES AND TABLES INDEX

Figure 3.0-1 FDA Recall Notices For Injectable Products, Years 2010-2019.....	3	Figure 5.1.2-3 Placement Of Container Within The Inspection Hood During Inspection.....	14
Figure 3.0-2 FDA Recall Notices For Particles In Injectable Products, Years 2010-2019.....	4	Figure 5.2-1 Locations Where Particles Were Seeded Into Or Onto Containers (Vials, Cartridges, And Syringes) In Prepared Test Kits	15
Table 3.2.2-1 Inspection Conditions and Acceptance Criteria for Visible Particles Found in the USP, EP, and JP.....	7	Table 5.2-1 Summary of Nominal Particle Size by Material	16
Table 4.1.1-1 Threshold Value to Use when Classifying Particles as Visible or Subvisible (by methods more sensitive as compared to the unaided eye).....	9	Table 5.2-2 Measurement Method Used to Determine Nominal Particle Size	16
Figure 4.1.2-1 Microscope Reticle Design For Elastomer Component Particle Analysis	10	Figure 5.2-2 Examples of Feret Max And Rect A And B Particle Size Measurements	17
Table 5.1-1 Key Attributes of Proposed Inspection Conditions and Method	12	Figure 5.3-1 Probability Of Detection For Particles And Fibers Of Varying Size During Inspection Of Empty Glass Containers.....	17
Figure 5.1.2-1 Visual Inspection Workstation.....	13	Figure 5.3.1-1 Probability Of Detection For Particles And Fibers Of Varying Size During Inspection Of Empty Glass Containers With Size Normalized To Apparent Area.....	18
Figure 5.1.2-2 Example Of Container Inspection Using Recommended Method And Relative Placement In The Inspection Hood.....	13		

Figure A1	Process Map of the Pilot (method development) and Qualification Strategy ..	22	Figure A18	Comparison of inspection performance by both supplier and operator for fibers >300 µm.....	32
Figure A2	Method Qualification Sample Generation Stratification	23	Figure A19	Box plot of performance by supplier for fibers >300 µm	33
Figure A3	Process Map of Final Method Qualification Study	24	Table B1	Orbital Shaker RPM Ranges.....	34
Figure A4	Interval plot of Supplier 1 results for particles >100 µm for each operator	25	Figure B1	Flowchart showing the use of the specified reticle to determine status of any observed particles on the filter.....	37
Figure A5	Interval plot of replicate inspection results for Supplier 1, Operators 1 vs 3 and Operator 2 vs 3, for particles >100 µm	25	Table C1	Summary of Nominal Particle Size by Material	38
Figure A6	Interval plot of Supplier 1 results for particles >300 µm for each operator	26	Figure C1	Shape factor vs size for the particles and fibers seeded into test vials.....	38
Figure A7	Interval plot of replicate inspection results for Supplier 1, Operators 1 vs 3 & Operators 2 vs 3, for fibers >300 µm.....	26	Figure C2	Graphic comparison of test kit composition (kits A, B, and C)	39
Figure A8	Interval plot of Supplier 2 results for particles >100 µm for each operator	27	Figure C3	Distribution of time required to complete inspection of test kit	40
Figure A9	Interval plot of Supplier 2 group performance for particles >100 µm.....	27	Figure C4	Particle inspection results with inspectors having prior experience with empty containers (Yes) and those without such experience (No)	40
Figure A10	Interval plot of Supplier 2 results for fibers >300 µm for each operator	28	Figure C5	Fiber inspection results with inspectors having both prior experience (Yes) with empty containers and those without such experience (No)	41
Figure A11	Interval plot of Supplier 2 group performance for fibers >300 µm	28	Figure C6	Probability of detection for particles of differing type and size	41
Figure A12	Interval plot of Supplier 3 results for particles >100 µm for each operator	29	Figure C7	Probability of detection for fibers of differing type and size	42
Figure A13	Interval plot of Supplier 3 group performance for particles >100 µm.....	29	Figure C8	Probability of detection for particles in various container types and sizes.....	42
Figure A14	Interval plot of Supplier 3 results for fibers >300 µm for each operator	30	Figure C9	Probability of detection for fibers in various container types and sizes	43
Figure A15	Interval plot of Supplier 3 group performance for fibers >300 µm	30	Figure C10	Boruta Plot of inspection study results demonstrating factors significant to reliable inspection performance.....	43
Figure A16	Comparison of inspection performance by both supplier and operator for particles >100 µm	31			
Figure A17	Box plot of performance by supplier for particles >100 µm	32			



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org